REGN Maintained by Piper Sandler -- Price Target Raised to $865

Regeneron Pharmaceuticals (NASDAQ:REGN) is positioning itself as a contender in the weight loss market with two promising drugs: olatorepatide, which showed 19% weight loss in trials, and trevogrumab, which helps preserve lean mass. Regeneron's revenue grew 17% YoY to $4.3B in Q2, driven by Dupixent's 38% YoY sales increase to $6B. Eylea HD sales rose 52% YoY to $596M, mitigating declines in the original Eylea.

A report found 15 biotech companies, including ThermoFisher and MilliporeSigma, manipulated antibody assay images. Regeneron's free gene therapy for hearing loss sparked debate. Novartis faced setbacks with failed trials. FDA introduced fast-track programs for ultra-rare diseases and a PreCheck initiative for drug manufacturing.

Regeneron (REGN) announced the EMA's CHMP recommended an updated dosing regimen for Libtayo (cemiplimab) across all approved EU indications. The new regimen reduces dosing frequency after 12 weeks. The European Commission will make a final decision in the coming months. Libtayo is approved in over 30 countries for various cancers. REGN stock closed at $769.34, up 2.31%.

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

Regeneron (REGN) announced the EMA's CHMP recommended approval for an extended dosing schedule of Libtayo (cemiplimab) across all approved indications. The new regimen includes a higher dose every six weeks after an initial 12-week regimen. The European Commission is expected to make a final decision in the coming months.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced on 16 October 2026 that the European Medicines Agency's CHMP recommended a less frequent dosing schedule for its cancer drug Libtayo, moving from every three weeks to every six weeks after an initial 12-week period. The change, if approved by the European Commission, would apply across all of Libtayo's approved cancer indications in the EU.